Olivier Elemento, Director of Englander Institute for Precision Medicine at Weill Cornell Medicine, shared NCI Division of Cancer Biology’s post on LinkedIn, adding:
“The gap between AI’s promise and clinical reality in oncology is stark:
Only 1% of FDA-approved AI medical devices have RCT evidence, while 34% of AI treatment recommendations contradict clinical guidelines.
Join us Sept 23 at 11am ET as we confront the critical challenges blocking AI adoption in cancer care:
- Why aren’t oncologists adopting AI despite the hype?
- What evidence standards should AI meet before guiding patient care?
- How do we move from retrospective validation to prospective trials?
We need to ensure AI transforms cancer care safely and effectively. The technology exists, but trust must be earned through evidence—and we’re far from that today.”
Quoting NCI Division of Cancer Biology’s post:
“On September 23 at 11:00 am ET, Olivier Elemento, Amber Simpson, and M Ryan Weil, Ph.D., PhD will discuss integrating AI in clinical care and clinical trials for oncology during a National Cancer Institute (NCI) Cancer AI Conversation.”
More posts featuring Olivier Elemento.